"Treatment with glecaprevir and pibrentasvir for 12 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or 5 chronic kidney disease and HCV infection," the authors write.
Lixivaptan is a potent, selective vasopressin V2 receptor antagonist which has been found to delay the progression of an autosomal dominant form of polycystic kidney disease.
The updates include a primer on HCV resistance and guidance on treating patients who have undergone kidney transplantation.
In addition, for adult patients with CKD G3a-G5 not on dialysis, the new guideline indicates that calcitriol and vitamin D analogs should not be routinely used.
The risk for premature death increased by 62% and 42% for stage 3 CKD patients with vitamin D deficiency and elevated parathyroid hormone levels, respectively.
MPR interviewed Dr. John Stoffel to discuss the strategies for diagnosis and management of urinary retention in MS patients, as well as his recommendations for optimal care for these patients.
The researchers found in an eGFR trajectory analysis that 10.1% of participants were rapid decliners, with a mean decrease of 2.9 mL/min/1.73 m²/year.
Vabomere is a combination antibiotic that includes meropenem, a penem antibacterial, and vaborbactam, a non-suicidal beta-lactamase inhibitor.
Phase 2 trials have shown to be associated with reductions in urine protein levels following treatment with OMS721 in patients with lgA nephropathy.
The vaccine consists of the FimH bacterial adhesion protein as well as a new adjuvant designed to induce an immune response to prevent bacterial colonization of the urinary tract.
Specifically, the following presentations will no longer be available: 125mg/5mL; 100mL bottles (anticipated final date of availability: April 1, 2018), 250mg/5mL; 50mL bottles (anticipated final date of availability: January 15, 2018), 250mg/5mL; 100mL bottles (anticipated final date of availability: February 15, 2018)
"Our results highlight the opportunity to intervene both at the provider and the site level to improve testosterone prescribing," the authors write.
Based on one retrospective review of 8 years of compliance, the strongest predictors of shorter length of stay were identified as no nasogastric tube, early mobilization, early oral nutrition, early removal of epidural and urinary catheter, and nonopioid analgesia.
"We look forward to FDA's review of our application for a potential new treatment option for the millions of people living with OAB," said Bernhardt Zeiher, MD, president of Development at Astellas.
"The use of acupuncture with or without clomiphene, compared with control acupuncture and placebo, did not increase live births," the authors write.
The team found that elevated levels of the suPAR protein triggered the start and progression of chronic kidney disease in those with two copies of APOL1 gene variants.
The researchers note that nonneurogenic chronic urinary retention was defined by the workgroup as an elevated post-void residual of more than 300mL, which persisted for at least 6 months and was documented on at least 2separate occasions.
In addition, the companies are conducting other mechanistic studies that will evaluate the potential mechanisms by which empagliflozin may affect renal outcomes in patients with CKD.
In their paper, the authors noted that "healthy urinary tracts host a ubiquitous, complex microbial community" and that the presence of these microorganisms are often beneficial to overall well-being.
Since oxidative stress is known to worsen DKD, study authors sought to review available data on the possible benefits of chronic antioxidant supplementation on DKD progression.
These undeclared ingredients may interact with nitrates contained in some prescription medications (eg, nitroglycerin), and may decrease blood pressure to dangerous levels.
The supplement contains pumpkin seed and soy germ extract, and Synetrim CQ, a botanical that further promotes bladder control by aiding metabolic health and managing weight.
The association between melanoma among PDE5i users was only statistically significant for male patients with low PDE5i exposure and with low-stage melanoma.